Gaucher disease, a lysosomal glycolipid storage disorder, re-
Introduction
Gaucher disease is the most common human lysosomal storage disorder. It is caused by mutations in the structural gene for the enzyme glucocerebrosidase (GC)1 (EC 3.2.1.45; reviewed in references 1 and 2) . Decreased GC activity leads to the accu- 1 . Abbreviations used in this paper: BMT, bone marrow transplantation; GC, glucocerebrosidase; IMDM, Iscove's modified Dulbecco's medium; LTBMC, long-term bone marrow culture; LTCIC, long-term culture initiating cells; LTR, long terminal repeat; VPF, vector-producing fibroblast. mulation of the substrate glycolipid in macrophages throughout the reticuloendothelial system. Extensive glycolipid storage results in the symptoms of hepatosplenomegaly, hypersplenism, and lytic bone lesions. There are three clinically distinct forms of Gaucher disease: nonneuronopathic (type 1), acute neuronopathic (type 2), and subacute neuronopathic (type 3).
Allogenic bone marrow transplantation (BMT) results in the replacement of the reticuloendothelial system with donorderived macrophages produced from engrafted hematopoietic stem cells. BMT has been shown to have a beneficial effect on the somatic symptoms of patients with types 1 and 3 Gaucher disease, although the long-term effects on neurologic and intellectual function remain to be determined (3) (4) (5) . Currently, only allogeneic transplants from fully histocompatible donors are deemed appropriate treatment for Gaucher disease, owing to the higher risks of graft rejection or graft-versus-host disease with less well-matched donors (6) .
Current progress in gene transduction techniques and the cloning ofthe normal human GC cDNA (7, 8) allows consideration of gene therapy for Gaucher disease (reviewed in references 9 and 10). The insertion of a normal GC gene into a Gaucher patient's bone marrow stem cells followed by an autologous BMT (gene therapy) could potentially restore macrophage GC activity without the risk of immunologic complications from an allogeneic transplant. Retroviral-mediated transfer of the human GC cDNA has been shown to produce physiological levels of GC in murine bone marrow (1 1-13), Gaucher fibroblasts (14, 15) , and Gaucher bone marrow cells ( 16) .
In the present study we report construction of a high-titer, helper-free retroviral vector, L-GC, which contains the human GC cDNA under control of the Moloney murine leukemia virus long-terminal repeat (LTR). Using a protocol that we had previously developed to produce highly efficient gene transfer into normal human marrow ( 17) , we have successfully transduced Gaucher marrow with the L-GC vector. The transduced marrow was maintained in long-term bone marrow culture (LTBMC) for 5 mo. Vector-derived GC expression was measured after various periods of culture. The mature myelomonocytic cells which were produced in the nonadherent cell fraction of the LTBMC had levels of vector-derived GC mRNA, immunoreactive protein, and enzymatic activity in the range of normal myelomonocytic cells. These results demonstrate the ability of retroviral-mediated GC gene transfer into hematopoietic progenitor cells to correct the genetic defect ofGaucher disease in the specific cells involved in the pathogenesis.
A. D. Miller, Seattle, WA (18, 19) . L-GC was constructed by placing a normal human GC cDNA between the 5' LTR-leader (Psi) region fragment (EcoRI -EcoRi ) and 3' LTR and pBR322 fragment (Clal / EcoRI) of pLNCX (18, 20) . The L-GC vector plasmid was co-transfected with pSV2Neo into the Psi2 ecotropic packaging cell line (21) , then cross-transduced into PA317 amphotropic packaging cells (American Type Culture Collection, Rockville, MD). PA317 clones were obtained as described (13) . PA317 cells were maintained in DME high glucose (Irvine Scientific, Santa Ana, CA) with 10% FCS. A PA317 VPF clone (PA317 / L-GC6), which transduced maximal levels ofenzymatically active human GC into 3T3 cells, was selected for further study. Absence of infectious helper virus was verified by the lack of amphotropic env sequences detectable by polymerase chain reaction (PCR) of the transduced 3T3 cells (22) .
Source ofhuman marrow. Marrow was obtained from a 4-yr-old female with type 3 Gaucher disease as backup marrow harvest before a matched, unrelated donor bone marrow transplant. The patient had presented at 1 yr of age with massive splenomegaly. She underwent a splenectomy at 2 yr of age, owing to secondary respiratory compromise. At the time ofmarrow collection, she had massive hepatomegaly and oculomotor apraxia. On biopsy, her bone marrow was 50% replaced by typical Gaucher cells; her liver biopsy showed minimal hepatic fibrosis. She added to a final concentration of 4 ,g/ml.
Co-cultivation was allowed to proceed for 48 h, with the addition of 0.5 vol fresh medium and additional polybrene after 24 h. The concentrations of IL-3 and IL-6 were maintained throughout the period of prestimulation and co-cultivation. After the co-cultivation period, nonadherent marrow cells were obtained by flushing ofthe VPF monolayer. The cells were plated for several hours in fresh preculture media to allow adherence of VPF which had been collected. After the adherence step, nonadherent marrow cells were collected and washed, and viable cell numbers were counted by trypan blue exclusion.
Clonogenic assayfor hematopoietic progenitors. Directly after gene transfer, hematopoietic progenitor cells were enumerated using the CFU-granulocyte, erythrocyte, monocyte, megakaryocyte (GEMM) assay as described ( 17) . The rates of transfer of the neo gene were determined by measuring the percentage of colony-forming progenitors which were resistant to G418 (Geneticin; Sigma Chemical Co.). For each sample, four replicate plates were made and G418 (1 mg/ml active compound) was added to two of these. 5 X 104 cells per plate were used when assaying unseparated mononuclear cell preparations and between 200 and 1,000 cells were used when assaying CD34+ cells. These plating densities had been determined empirically to yield -100 colonies per plate, which is the upper limit that produces distinct, individual colonies. The numbers of total and G418-resistant progenitor-derived colonies were counted after 14 d. In all experiments, marrow transduced by the L-GC vector, which does not contain the neo gene, was completely inhibited from colony formation by this concentration of G4 8.
LTBMC. Human LTBMC were initiated immediately after gene transfer. Transduced CD34+ cells were maintained in LTBMC by reseeding onto irradiated (20 Gy) autologous stroma, to sustain clonogenic progenitors. Stromal cells were maintained in IMDM with 12% horse serum, 12% FCS, 1 X 10-6 M hydrocortisone, 1 X I0-4M 2-mercaptoethanol, 100 U/ml penicillin, and 10 tg/ml streptomycin. Primary stromal layers were harvested when confluent by incubation at 37°C for 20 min in 0.15% collagenase (type 1, Sigma Chemical Co.). After irradiation, stroma was seeded into 25-cm2 filter vent flasks (Costar) in 10 ml of media at a concentration of 1 X I05 cells per ml. The next day, the medium was removed and transduced CD34+ marrow cells were added to the stroma in 10 ml oflong-term culture medium at a concentration of 5 X I04 cells per ml. The medium used for LTBMC was: IMDM with 30% FCS, 1% deionized BSA, 5% phytohemagglutinin-stimulated human lymphocyte conditioned medium, 5% 5637 CM, 10-6 M hydrocortisone, l0-4 M 2-mercaptoethanol, 100 U/ml penicillin, 10 ,g/ml streptomycin, 2 mM L-glutamine, and 25 ng/ml recombinant human granulocyte/macrophage colony-stimulating factor (GM-CSF) ( 17) . Long-term cultures were fed at 3-5-d intervals by removing 75% of the spent medium and nonadherent cells and replacing with an equal volume of fresh medium. Cells collected from each culture during the media changes were used for Northern and Western blot or GC enzyme assay.
Northern blot analysis. Cell pellets collected from LTBMC at the times ofmedia changes ( -1 x 106 cells per sample) were washed once in 10 ml Ix PBS before nucleic acid extraction. Pellets for RNA were resuspended in 200 ,ul of PBS and kept on ice until lysis in 4 M guanidine isothiocyanate solution (24) . Extraction ofRNA, gel electrophoresis, and nucleic acid transfer were as described ( 11) .
Western blot and enzyme assay. Nonadherent cells for protein analysis were obtained from LTBMC in the manner previously described. Pellets were washed four times in 10 ml ofPBS to remove proteins from the serum-rich culture medium. Cells were kept on ice until assayed or stored at -200C. Western blots and enzyme assay for human OC were performed as described ( 11) .
Results
Generation and characterization of a PA317 clone producing the L-GC retroviral vector. We constructed a recombinant retroviral vector plasmid, L-GC, containing the normal human GC cDNA between the Moloney murine leukemia virus 5' and 3' LTR (Fig. 1) . Clones ofthe amphotropic packaging cell line PA3 17 producing L-GC virus were derived as described ( 13) . A clone, PA317/L-GC6, was selected for use in this study because it transduced high levels of immunoreactive human GC protein into target 3T3 cells (data not shown).
To determine the number of copies of the L-GC vector provirus contained in the PA3 17 /L-GC6 clone, genomic DNA was analyzed by Southern blot. DNA was digested with EcoR1, which cuts once in the provirus and releases fragments ofvarying length for each integrant, dependent upon the location of the nearest restriction site in the DNA flanking the provirus. The blot was probed with the normal human GC cDNA (Fig. 2  A) . The upper band, which is common to both the control cell line PA317/LN and the PA317/L-GC6 clone, represents the endogenous murine GC gene, which hybridizes with the human GC probe at low stringency. PA3 17 /L-GC6 was shown to contain at least six additional hybridizing bands, and hence contains at least six copies of integrated L-GC provirus.
To analyze expression of GC protein in the PA3 17/L-GC6 cells, we performed a Western blot analysis of solubilized cell proteins. We used the monoclonal antibody 8E4, which is specific for human GC (25) . The second lane in Fig. 2 Finally, we quantitated the human GC enzymatic activity produced in the PA31 7/L-GC6 clone. Normal human marrow had a total of21 1 U ofactivity, and > 75% ofthis was immunoprecipitated by 8E4 (Fig. 2 C) . As expected, none of the murine GC in the parental PA3 17 human GC-specific antibody. The PA317 /L-GC6 cell line produced approximately threefold more GC than the parental PA3 17 cell line, and the increment of activity was precipitated by 8E4. These results demonstrate that the increased total level of GC enzyme activity in the PA3 17 /L-GC6 clone was due to expressed human GC. Based upon these results demonstrating the high level offunctional GC produced by the PA3 17/ L-GC6 clone, it was used for subsequent studies of gene transduction of the Gaucher marrow.
Comparison ofgene transfer efficiency into the progenitor cells in whole-marrow versus CD34+ cells. To measure the efficiency of gene transfer into the hematopoietic progenitor cells 344 Nolta et al. 
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of the Gaucher marrow, we used the LN vector which carries the dominant selectable neo gene. Gene transfer efficiency was compared using either the total mononuclear cell fraction of the marrow or progenitor cells enriched by immunomagnetic selection of the CD34+ cells. Marrow cells were prestimulated with medium containing IL-3 and IL-6 and co-cultivated on PA317 cells producing the LN vector. Samples of the LNtransduced marrow were plated in methylcellulose-supported colony-forming assay with or without G418.
Examination of the frequency of colony-forming cells in the absence of G418 reveals the degree of purification of progenitor cells produced by the CD34 enrichment. From 4 x 105 mononuclear marrow cells plated in experiments 1,3,4, and 5, a total of 795 colonies were formed in the absence of G418 (0.20% colony-forming progenitor cells, Table I ). The CD34-enriched marrow formed 593 colonies from 4,600 cells plated in five separate experiments (12.9% progenitor cells). Thus, the CD34-immunomagnetic sorting procedure resulted in an -65-fold enrichment of colony-forming cells (range 36-133-fold).
Of the colonies that formed from the LN-transduced marrow, 40-45% were resistant to G418 (Table I) . In each experiment, marrow was also transduced with the vector L-GC, which does not contain the n eo gene. G418-resistant colonies were never seen in the L-GC-transduced marrow samples, demonstrating the stringency of the selection for neo gene transfer at the concentration of G418 that was used. (Fig. 3 B) . A vector band of 2.5 kb is seen in the LN-transduced marrow, while the L-GC-transduced cells serve as a negative control for neo RNA. Fig. 3 C shows RNA from the same LTBMC, harvested 3 and 5 mo after transduction with L-GC. Again, the blot was hybridized with the human GC probe. Expression of the vector-derived GC transcripts at levels equal to or greater than endogenous GC mRNA levels persisted. The continued production of mature hematopoietic cells expressing vector transcripts for up to 5 mo suggests that we have transduced longterm culture initiating cells (LTCIC), a primitive population of progenitor cells (28) . Western blot analysis of GC levels in L-GC transduced Gaucher marrow. Western blot analysis was done to assess the levels ofGC protein produced in nonadherent cells from transduced Gaucher cells from LTBMC. collected from three separate LTBMC 1 mo after transduction. GC enzyme activity was quantitated as described ( Fig. 2 C legend) . (Fig. 5) . The LN-transduced Gaucher marrow had only 16 .9% (±3.3, SEM) of normal GC activity, which is in the range that has previously been observed for cells from patients with type 3 Gaucher disease (29) . After transduction by the L-GC vector, the Gaucher marrow contained increased levels of enzymatic activity (58. 1 %± 1 1.0 of normal).
Discussion
Our results demonstrate high-efficiency transfer and persistent expression of the human GC gene by the L-GC retroviral vector in bone marrow cells from a patient with type 3 Gaucher disease. Expression of GC in the myelomonocytic cells pro4uced by the transduced marrow maintained in LTBMC was confirmed at the levels of both RNA (by Northern blot analysis) and protein (by Western blot analysis and GC enzyme assay). The continued expression of GC for 5 mo in LTBMC demonstrates that stable transduction of long-lived human hematopoietic progenitor cells has been achieved. These LTCIC have been postulated to be closely related to the pluripotent hematopoietic stem cells that produce hematologic reconstitution after BMT (28) and would be the specific target for gene transfer for human gene therapy.
To optimize the extent of retroviral-mediated gene transfer into LTCIC, we precultured the marrow with medium containing IL-3 and IL-6 before co-cultivation with the vector-producing cells. We and others have found that this combination of growth factors causes an increase in the number ofcycling progenitor cells and a corresponding increase in the level of gene transfer by retroviral vectors ( 17, 30, 31 ).
We directly compared the gene transfer efficiency using either the total marrow mononuclear cell fraction or a population enriched for progenitor cells by immunomagnetic isolation of CD34' cells. The CD34' fraction of human marrow has been demonstrated to produce hematologic reconstitution after autologous BMT and therefore contains true pluripotent hematopoietic stem cells (32) . Equal extents of gene transfer into the progenitor cells of each population were achieved, despite an -65-fold enrichment for the target progenitor cells in the CD34+ fraction. The ability to use purified cell preparations for clinical gene therapy will simplify the logistics of handling the large numbers ofcells needed for autologous BMT. As further advances are made into identification of the characteristics of human hematopoietic stem cells, it may be possible to further purify the target cells.
The gene transfer efficiency we obtained using the progenitor cells in marrow from the Gaucher patient (40-45%) was similar to levels we have previously reported with marrow from normal donors, when using the same protocol ( 17) . Therefore, the presence of numerous Gaucher macrophages in the marrow did not appear to affect the process ofretroviral vector transduction. These results imply that retroviral-mediated gene transduction ofGaucher marrow is technically feasible for clinical gene therapy.
The persistent expression of vector-derived GC in progeny of the transduced cells in LTBMC for 5 mo demonstrates that marrow from patients with Gaucher disease can be effectively and stably transduced by retroviral vectors. After transduction with the L-GC vector, which carries the normal GC cDNA, marrow from a Gaucher patient produced -60% of normal GC levels. GC expression at this level should be of clinical benefit, in that heterozygous Gaucher carriers expressing 50% of normal GC levels are asymptomatic (33) .
The nonadherent cells from long-term culture which were analyzed for GC expression were primarily mature myelomonocytic, as shown by Wright/Giemsa and nonspecific esterase staining. We observed sustained expression of GC RNA from the L-GC vector in these cells for as long as 5 mo, which was the duration of LTBMC. The expression of vector-derived GC in mature monocytoid cells is significant because they are the specific mature cell type that must be corrected for gene therapy of Gaucher disease.
Our studies represent a significant advance over the prior report of Fink et al. (16), because we have achieved normal levels of GC expression in marrow from a Gaucher patient without the need to select for transduced cells with G4 18. The ability to efficiently transduce progenitor cells without a requirement for drug selection will be important for clinical applications, inasmuch as G418 has been shown to reduce the ability of marrow to reconstitute mice (34, 35) , and may similarly compromise human marrow. 
